IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM - Generic Drug Details

What are the generic drug sources for iothalamate meglumine; iothalamate sodium and what is the scope of patent protection?

Iothalamate meglumine; iothalamate sodium is the generic ingredient in one branded drug marketed by Mallinckrodt and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM at DailyMed

US Patents and Regulatory Information for IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt	VASCORAY	iothalamate meglumine; iothalamate sodium	INJECTABLE;INJECTION	016783-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Iothalamate Meglumine and Iothalamate Sodium: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

Iothalamate meglumine and iothalamate sodium are older iodinated contrast media used in radiology, including contrast-enhanced imaging and certain urologic applications. Their market trajectory is shaped by (1) price pressure and contracting dynamics in hospital formularies, (2) supply-chain stability and quality of manufacturing for sterile injectables, and (3) competitive displacement by newer low-osmolar and iso-osmolar iodinated agents, plus modality shifts that reduce contrast intensity or frequency.

What is the market structure for iothalamate salts?

Iothalamate products are prescription-only iodinated contrast media delivered as sterile injectable solutions. The commercial market clusters around hospital procurement channels, radiology group buying, and government or payer-influenced formulary placement in many geographies.

Primary demand drivers

• Imaging volume in CT, fluoroscopy, and related interventional radiology settings.
• Retained use in specific clinical workflows where iothalamate salts have established protocols.
• Procurement behavior that favors multi-source supply, predictable lead times, and stable pricing under group purchasing arrangements (GPA) and tender cycles.

Primary commercial headwinds

• Long-term substitution risk: newer low- or iso-osmolar iodinated contrast agents typically gain formulary preference due to perceived tolerability and consistent imaging outcomes.
• Consolidation in hospital purchasing increases buyer leverage, pushing down unit prices for legacy agents.
• Lower pricing reduces incremental margin headroom, making new entrants and capacity expansions harder unless they can secure cost leadership or unique supply advantages.

How do competitive dynamics affect pricing and volume?

Competition in iodinated contrast is price-led at the contract and tender level, with performance and tolerability shaping formulary decisions. Iothalamate salts face displacement pressure from brands with entrenched hospital accounts and from generics where procurement policies permit.

Competitive forces

• Formulary switching: hospitals and health systems review contrast agent performance and use protocols to standardize. Once standardized, switching costs rise.
• Tender cycles: repeat bids often compress prices for legacy products.
• Clinical guideline inertia: long-standing order sets may sustain iothalamate use even as newer agents expand.

Net effect on iothalamate unit economics

• Volume can remain steady or decline slowly in mature markets, while revenue per unit tends to compress.
• Margin recovery requires either (a) differentiated supply, (b) regional contracting strength, or (c) a niche application mix that keeps utilization stable.

What is the evidence base for market-use continuity?

Iothalamate meglumine and iothalamate sodium remain referenced in prescribing information and clinical protocols as iodinated contrast agents for specific imaging contexts. Their continued presence in product labels supports ongoing use in clinical practice even as new agents dominate broader adoption.

Regulatory and label continuity

• Iothalamate meglumine is an iodinated contrast medium.
• Iothalamate sodium is an iodinated contrast medium. Both are handled under sterile injectable drug product frameworks consistent with ongoing distribution in radiology supply chains. (Sources: prescribing information and regulatory label listings [1], [2].)

How does supply-chain risk shape financial trajectory?

For sterile injectables, financial performance is tied to production uptime, sterile manufacturing compliance, and logistics. For iothalamate salts, investors and business planners typically underwrite results around:

Operational drivers

• Manufacturing yields and sterility assurance throughput for solutions.
• Batch release timelines (quality testing and documentation).
• Ability to maintain supply continuity under procurement contract volume commitments.

Financial consequences

• Any recurring supply disruption creates revenue loss and damages contract renewal prospects.
• Stable supply improves contract retention and supports price resilience during tender cycles.

What does the financial trajectory likely look like in mature markets?

For older, commodity-like imaging drugs, the typical financial trajectory is:

Phase 1: Mature revenue base

• Revenue tracks imaging demand more than innovation.
• Pricing declines are gradual but persistent due to competitive pressure and generic availability dynamics.

Phase 2: Margin compression

• Unit price reductions outpace volume gains.
• Higher regulatory and sterility-related costs raise sustaining spend.

Phase 3: Niche retention or regional differentiation

• Companies that maintain hospital penetration in specific modalities can avoid steeper declines.
• Regional distributor reach can offset national price pressure if contracting is favorable.

In this structure, iothalamate meglumine and iothalamate sodium are expected to exhibit:

• Gradual revenue pressure driven by competitive substitution.
• Limited upside unless a company secures favorable contract economics or expands supply reliability.

What patent and exclusivity dynamics are relevant to iothalamate salts?

Iothalamate salts are long-established. Their active ingredients are not typically supported by broad, long-horizon patent exclusivity in the way that modern small molecules and biologics are. In practice, market performance is dominated by:

• Generic and multi-source competition.
• Contract pricing, supply continuity, and local regulatory clearances.

This structure shifts the revenue story away from innovation-led growth and toward commercial execution and supply chain performance. (Context: product labeling and regulatory listings for iothalamate salts [1], [2].)

How do procurement and payer dynamics affect revenues?

Hospital purchasing and reimbursement frameworks influence uptake and contract pricing.

Procurement channels

• Group purchasing organizations (GPOs) and health-system tenders.
• Distributor contracts that bundle multiple contrast agents.
• Formularies that specify preferred agents and allow limited alternatives.

Revenue implications

• Even with stable clinical use, pricing pressure is sustained through tender-based selection.
• Higher purchasing volumes can be offset by lower unit pricing.

What are the product-level market characteristics for each salt?

Iothalamate meglumine

• Widely used as an iodinated contrast medium in imaging contexts.
• Commercial performance tends to track hospital purchasing behavior and contract renewal cycles. (Source: product label listing [1].)

Iothalamate sodium

• Also used as an iodinated contrast medium.
• Its commercial trajectory is likewise tied to tender pricing and radiology protocol adoption. (Source: product label listing [2].)

What financial metrics matter for investors and R&D planners?

Given the mature, competitive nature of iodinated contrast agents, the financial lens usually prioritizes:

Metric	Why it matters for iothalamate salts	What to watch
Net sales per unit	Tender price compression is persistent in legacy contrast	Contract renegotiations, GPO rebates, distributor margins
Gross margin	Sterile manufacturing costs and QC costs pressure margins	Batch release efficiency and defect/rework rates
Fill-and-finish uptime	Supply continuity drives contract retention	Manufacturing uptime, capacity constraints
Recall or quality events	Sterile injectables are sensitive to compliance events	Regulatory inspections, CAPA status, batch disposition
Market share stability	Use can persist through protocols even as newer agents expand	Switch rates in radiology order sets

What scenarios are most consistent with market behavior?

Scenario A: Stable utilization, falling price

• Imaging volumes remain adequate; hospitals reduce cost through tender renewals.
• Revenue declines faster than volume, with margin pressure.

Scenario B: Contract consolidation, limited growth

• Fewer suppliers win larger contracts.
• If an iothalamate supplier holds contracts, sales remain stable; otherwise, revenue erodes.

Scenario C: Supply-driven outperformance in a constrained market

• If competitors face shortages, the supplier with reliable manufacturing captures demand.
• Results become lumpy but can support temporary pricing power.

These scenarios align with how sterile contrast products perform under tender procurement and supply variability. (Anchored by label-defined product use and ongoing regulatory availability [1], [2].)

What does this mean for near- to mid-term financial trajectory?

Over the near to mid-term, a typical trajectory for iothalamate meglumine and iothalamate sodium in mature markets is:

• Revenue: flat-to-down due to substitution and tender price compression.
• Margins: down or constrained unless a supplier achieves superior cost structure and maintains supply reliability.
• Cash flow: sensitive to working capital and manufacturing scheduling because injectable drugs often involve longer lead times, batch release delays, and inventory planning tied to contract schedules.

Absent product innovations or new clinical indications with scale, performance depends more on execution than on scientific differentiation.

Key Takeaways

• Iothalamate meglumine and iothalamate sodium are mature iodinated contrast media with market behavior dominated by hospital procurement, tender pricing, and supply-chain execution.
• Competitive substitution by newer iodinated contrast agents drives long-run unit price pressure and limits upside from volume growth.
• Financial trajectory is most consistent with flat-to-down revenue and constrained margins in mature markets, with potential short-term outperformance only when supply reliability and contract awards favor a given manufacturer.
• Operational uptime and sterile manufacturing compliance are the primary determinants of sales continuity and gross margin stability for these sterile injectables.

FAQs

1) What primarily drives iothalamate contrast sales?
Hospital imaging demand and procurement contract outcomes, with utilization shaped by radiology protocols and tender-based agent selection.

2) Does innovation drive growth for iothalamate salts?
Growth is typically not innovation-led; performance is driven more by commercial execution, cost structure, and supply continuity in a mature competitive class.

3) Why does price compression persist in iothalamate products?
Group purchasing and tender mechanisms increase buyer leverage and favor lowest-cost supply within formulary constraints.

4) What is the biggest operational risk for financial outcomes?
Sterile injectable manufacturing disruptions or quality events that impair batch release and contract continuity.

5) What would indicate an improving financial outlook?
Contract wins that improve net sales per unit, stable or improved gross margin through manufacturing efficiency, and reduced tender losses through reliable supply.

---

References

[1] DailyMed. Iothalamate Meglumine Injection (label information and regulatory listing). https://dailymed.nlm.nih.gov/
[2] DailyMed. Iothalamate Sodium Injection (label information and regulatory listing). https://dailymed.nlm.nih.gov/